Peptide Initiative

Peptide profile · Weight Management

Survodutide

Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease

Strong human trialsResearch compound
~7 daysHalf-life (enabling once-weekly dosing)
Optimized for subcutaneous administration with C18 acylationBioavailability
4,231.6Molecular weight, Da

Molecular formula

C192H289N47O61

CAS number
2805997-46-8
PubChem
168429725
Developed · Phase 3 ongoing (2023-present)
Boehringer Ingelheim (co-invented with Zealand Pharma), Boehringer Ingelheim

Amino acid sequence

H-Ac4c-QGTFTSDYSKYLDERAAKDFI-K(C18 diacid via GS linker)-WLESA-NH2 (29 amino acids)

Weight ManagementUp to 14.9% weight loss at 46 weeks through dual GLP-1R and GCGR activation — enhancing both appetite suppression and energy expenditure beyond GLP-1 alone

0.9

Metabolic Health62% improvement in MASH without worsening of fibrosis at 4.8 mg (vs 14% on placebo), liver fat cut by at least 30% in up to 67% (vs 14%) , and comprehensive metabolic improvements including glycemic control and lipid profiles

0.9

Blood Sugar ControlHbA1c reductions up to 1.71% in type 2 diabetes with greater weight loss than semaglutide at equivalent glycemic efficacy

0.8

Ratings out of 10.

0.6 – 4.8mg

Every documented dose level

PhaseDoseFrequency
Initiation, part of a 20-week up-titration0.6 mgOnce weekly
26-week maintenance after escalation3.6 mgOnce weekly
26-week maintenance after escalation4.8 mgOnce weekly
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for significant body weight reduction in obesity & mash/nash resolution and liver fibrosis improvement

Best for

  • Significant body weight reduction in obesity

    Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • MASH/NASH resolution and liver fibrosis improvement

    Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Type 2 diabetes management with concurrent weight loss goals

    Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Enhanced metabolic outcomes through dual receptor engagement

    Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for weight management supportConsult your healthcare provider for alternatives to Survodutide based on your specific needs and medical history
Alternative weight management approachesSemaglutide (Wegovy/Ozempic)Liraglutide (Saxenda)AOD-9604
Non-injectable weight managementOral semaglutide (Rybelsus)Phentermine-topiramate (Qsymia)Lifestyle modifications

Do not use if

  • Personal or family history of medullary thyroid carcinoma (GLP-1 class warning)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known hypersensitivity to survodutide or excipients
  • History of pancreatitis (caution advised with GLP-1 receptor agonists)

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Survodutide use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Survodutide with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Survodutide injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (gastrointestinal events in 75% on survodutide vs 42% on placebo in the obesity trial ; nausea 66%, diarrhea 49% and vomiting 41% in the MASH trial ) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure.

Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential.

Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.

Phase 2 trial safety data in ~400 patients supports tolerability for up to 48 weeks, though long-term data beyond 1 year remains limited prior to potential regulatory approval. Cardiovascular outcome trials and long-term hepatic safety monitoring in MASH population are ongoing.

Not yet FDA-approved—all use remains investigational pending Phase 3 completion.


Common side effects · experienced by some users

Nausea

In the phase 2 obesity trial, gastrointestinal adverse events affected 75% of survodutide-treated patients versus 42% on placebo ; in the MASH trial, nausea itself affected 66% versus 23% . Dose-dependent and most pronounced during dose escalation. Odds ratio increases from 6.11 at 2.4 mg to 27.54 at 4.8 mg.

Management
Gradual dose escalation over 16-20 weeks significantly reduces nausea incidence and severity. Smaller meals, avoiding high-fat foods, and adequate hydration help. Symptoms typically diminish with continued treatment.

Vomiting

Frequently accompanies nausea during dose escalation. Dose-dependent occurrence related to dual GLP-1R and GCGR activation in the gastrointestinal tract and central nervous system.

Management
Slower dose titration. Anti-emetics if needed. Ensure hydration. May temporarily hold dose escalation if severe.

Diarrhea

Gastrointestinal disturbance from combined receptor activation affecting gut motility and secretion. Generally mild to moderate severity.

Management
Maintain hydration. Usually resolves with continued treatment. Dose adjustment if persistent.

Decreased Appetite

Expected pharmacological effect contributing to weight loss. Mediated through both GLP-1R and GCGR central nervous system effects on appetite regulation.

Management
Generally beneficial for the treatment goal. Ensure adequate nutritional intake despite reduced appetite. Monitor for excessive caloric restriction.

Serious side effects

Acute Pancreatitis

Rare but serious risk associated with GLP-1 receptor agonist class. Patients should be monitored for severe persistent abdominal pain.

Management
Discontinue survodutide immediately if pancreatitis is suspected. Seek emergency care for severe abdominal pain radiating to the back. Do not restart treatment if pancreatitis is confirmed.

Less commonConstipation and Abdominal Pain

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Survodutide
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Survodutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeMetformin — Complementary insulin-sensitizing mechanism with established cardiovascular benefits supports comprehensive metabolic management
  • SafeSGLT2 Inhibitors — Independent glucose-lowering and cardiorenal protective mechanisms complement survodutide's metabolic and hepatic benefits
  • SafeDietary Intervention — Caloric restriction synergizes with survodutide's appetite suppression and enhanced energy expenditure for maximal weight loss

With medications

  • CautionOther GLP-1 Receptor Agonists — Redundant GLP-1R activation with no additional benefit and increased gastrointestinal adverse events
  • CautionInsulin Secretagogues — Increased hypoglycemia risk when combined with agents that stimulate insulin secretion independent of glucose levels
  • CautionGlucagon for Hypoglycemia Rescue — Survodutide's glucagon receptor agonism may alter the pharmacodynamics of exogenous glucagon used in hypoglycemia emergencies

With supplements

  • SafeMultivitamins — Generally safe to take alongside Survodutide. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs weeks 1-16

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Survodutide is a dual GLP-1/glucagon receptor agonist designed to deliver even stronger weight loss and metabolic benefits than single-hormone drugs by activating two appetite and metabolism control pathways simultaneously.

The deeper mechanism

Survodutide is a potent dual GLP-1/glucagon receptor agonist engineered to activate both the GLP-1 receptor (promoting insulin secretion and appetite suppression) and the glucagon receptor (promoting energy expenditure and hepatic glucose metabolism).

The dual activation amplifies weight loss through complementary mechanisms: GLP-1 suppresses appetite and slows gastric emptying while glucagon increases energy expenditure, elevates metabolic rate through activation of brown adipose tissue thermogenesis, and promotes hepatic fat oxidation—collectively producing synergistic metabolic improvements exceeding single-hormone agonists.


What to expect

  1. Weeks 1-16

    What you might notice

    • Dose escalation period with gradual introduction
    • GI side effects (nausea, vomiting) are most common during this phase
    • Early appetite reduction and beginning of weight loss

    What's normal

    • Nausea is expected and typically peaks during dose increases
    • Appetite reduction begins early
    • Weight loss starts but accelerates as maintenance dose is reached
    • GI symptoms generally improve with continued dosing

    What's next

    • Complete dose escalation to target maintenance dose (3
    • 0 mg weekly)
    • GI tolerability typically improves as the body adjusts to each dose level
  2. Weeks 16-32

    What you might notice

    • Accelerating weight loss at maintenance dose
    • Improved glycemic markers if diabetic
    • GI side effects diminishing
    • Measurable improvements in metabolic parameters

    What's normal

    • Steady weight loss trajectory
    • HbA1c improvements in diabetic patients
    • Liver enzyme improvements in MASH patients
    • Reduced appetite stabilizes
    • GI side effects become less frequent

    What's next

    • Continue maintenance dosing
    • Clinical assessment of weight loss, metabolic parameters, and liver health markers
  3. Weeks 32-52+

    What you might notice

    • Continued weight loss approaching 10-15% of body weight
    • Sustained metabolic improvements
    • In MASH patients, potential histological improvement on liver biopsy

    What's normal

    • Weight loss may continue beyond 46 weeks (Phase 2 data suggested ongoing trajectory)
    • Metabolic parameters remain improved
    • Weight loss rate may gradually slow as new steady state is approached

    What's next

    • Long-term maintenance therapy
    • Phase 3 trials evaluating 76-week outcomes will define long-term efficacy and safety profile

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Survodutide over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

49 registered studies, 6 still enrolling.

49registered studies
6recruiting now
9phase 3 or 4
12with published results

By phase

Phase 1

20

Phase 3

9

Phase 2

4

No phase

16

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

49

Records only

0

About 17,065 people took part in the studies that actually administered Survodutide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT07768813 Phase 1Not Yet Recruiting44 enrolled

    A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

    Boehringer Ingelheim

  • NCT07754461 Phase 3Recruiting600 enrolled

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Boehringer Ingelheim

  • NCT07407348 Phase 1Recruiting80 enrolled

    A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

    Boehringer Ingelheim

See all 49 trials for Survodutide

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Survodutide is named as an intervention; studies that only mention it in passing are not.

How does survodutide differ from semaglutide and other GLP-1 agonists?

Survodutide is a dual agonist that activates both the GLP-1 receptor AND the glucagon receptor, while semaglutide only activates the GLP-1 receptor. The glucagon receptor component adds a fundamentally different mechanism — it increases energy expenditure, stimulates hepatic fat oxidation, and promotes thermogenesis. In head-to-head Phase 2 comparison, survodutide produced greater weight loss (8.7% vs 5.3%) than semaglutide at equivalent glycemic control in type 2 diabetes patients.

What is the MASH breakthrough therapy designation?

The FDA granted survodutide Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis. This was based on Phase 2 data showing improvement in MASH without worsening of fibrosis in 62% of patients at the 4.8 mg dose, compared to 14% with placebo . This designation accelerates the development and regulatory review process.

When might survodutide become commercially available?

Survodutide is currently in Phase 3 clinical trials. The SYNCHRONIZE obesity program and LIVERAGE MASH program are expected to report results in 2026-2027. Regulatory submissions could follow positive Phase 3 results, with potential approval estimated for 2027-2028, though timelines depend on trial outcomes and regulatory review.

Why does survodutide cause more GI side effects than some other treatments?

Survodutide stimulates both GLP-1 and glucagon receptors in the gastrointestinal tract and central nervous system, resulting in more pronounced effects on gut motility, gastric emptying, and appetite signaling compared to GLP-1-only agonists. In the phase 2 obesity trial, gastrointestinal adverse events affected 75% of patients versus 42% on placebo ; in the MASH trial, nausea affected 66% versus 23% . However, gradual dose escalation over 16-20 weeks significantly mitigates these effects, and most patients tolerate the medication well at maintenance doses.

Is the glucagon component of survodutide safe for diabetic patients?

Yes, the glucagon receptor agonism does not worsen glycemic control because it is balanced by the GLP-1 receptor component which promotes glucose-dependent insulin secretion. In Phase 2 diabetes trials, survodutide achieved comparable HbA1c reduction to semaglutide while providing superior weight loss. The dual agonism appears metabolically synergistic rather than antagonistic.

What Phase 3 trials are currently running?

Several Phase 3 programs are underway: SYNCHRONIZE-1 (obesity without diabetes, n=726), SYNCHRONIZE-2 (obesity with T2DM, n=755), SYNCHRONIZE-CVOT (cardiovascular outcomes, n=5,531), LIVERAGE (MASH with fibrosis, n=1,800), and regional trials in China and Japan. These represent one of the largest clinical development programs for a metabolic disease agent.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Survodutide, on one page.

Survodutide dosing protocol

Medical disclaimer

Survodutide is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

0.6 – 4.8 mg Once weekly · onset 1-2 weeks
Open the Survodutide calculatorSurvodutide calculator